About a fifth of ANCA-associated vasculitis patients have an eye disorder known as inflammatory ocular disease, a Mayo Clinic study shows. The research, published in the journal Rheumatology, was titled “Clinical characteristics of inflammatory ocular disease in anti-neutrophil cytoplasmic antibody associated vasculitis: a retrospective cohort study.” ANCA-associated vasculitis, or AAV, affects…
News
Although certain immune cells are present at lower levels in patients with anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV), it is due to non-specific renal injury rather than the disease itself, study shows. The study, “Alterations in circulating lymphoid cell populations in systemic small vessel vasculitis are non-specific…
Different types of ANCA-associated vasculitis occur in different ethnic groups, a study reports. The research, “Global ethnic and geographic differences in the clinical presentations of anti-neutrophil cytoplasm antibodyassociated vasculitis,” was published in the journal Rheumatology. Anti-neutrophil cytoplasm antibodies-associated vasculitis, or AAV, refers to three…
The protein TIMP1 is a promising biomarker of ANCA-associated vasculitis activity, according to a Japanese study that also identified markers of the disease’s damage to the kidneys and lungs. Altogether, the researchers identified nine proteins that could be suitable biomarkers. Researchers published their work in the journal Arthritis Research…
Lower levels of key immune system regulators in the kidneys of ANCA vasculitis patients may indicate more severe renal injury, according to a new study from China. The study, “Complement regulatory proteins in kidneys of patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis,” appeared in the journal…
T-cell-generated Signaling Molecule Plays Role in Development of Glomerulonephritis, Study Reports
A signaling molecule produced by a type of immune T-cell plays a key role in the development of the kidney inflammation glomerulonephritis, an Australian study reports. The molecule is interleukin-17, or IL-17. The cell that generates it is the gamma-delta (γδ) type of T-cell. And the kidney condition is myeloperoxidase (MPO) anti-neutrophil…
Maintenance Treatment After Rituxan for ANCA-associated Vasculitis Not Needed, Researchers Argue
Certain types of patients with ANCA-associated vasculitis do not require maintenance therapy if treated with a specific Rituxan (rituximab) approach, according to researchers at the University of Turin in Italy who followed patients for up to 11 years. The study, albeit small, might clear up some confusion about the…
Dutch scientists have identified different genes in Staphylococcus aureus — a kind of bacteria carried in the nostrils — in either patients with PR3-ANCA vasculitis or with MPO-ANCA-positive vasculitis. The results suggest that the genes they found are relevant in causing and prolonging the disease. The study, “Genetic loci…
Central Nervous System Involvement Seen Not to Affect Survival Rates in GPA Patients, Study Finds
A retrospective study has investigated the central nervous system’s (CNS) involvement in granulomatosis with polyangiitis (GPA) in a group of Greek patients. The study found that CNS involvement does not affect long-term patient outcomes. ANCA-associated vasculitis (AAV) refers to a group of rare diseases characterized by inflammatory cell infiltration and…
A review about the anti-neutrophil cytoplasmic antibody (ANCA) glomerulonephritis and vasculitis outlined the best way to characterize the different kinds of ANCA-associated disease in order to provide better treatment. The review, “ANCA Glomerulonephritis and Vasculitis,” was published in the Clinical Journal of the American Society…
Recent Posts
- Finding a little light on dark winter days is key with ANCA vasculitis
- Real-world data show high AAV remission rates with Tavneos
- GPA and EGPA overlap features linked to disease severity, survival risk: Study
- Starting a new year with ANCA vasculitis
- New analysis identifies phase-specific relapse risks in AAV treatment